65,437 trials
Bacterial Infections
Primary: Percentage of Participants With Early Clinical Response at 48-72 Hours After the First Infusion of Study Drug in the ITT Analysis Set. — 75.3; 79.9 Percentage of…
Dry Eye Syndromes
Primary: Change From Baseline in the Ocular Surface Disease Index© (OSDI©) Score — 42.44; 40.43; -10.29; -7.48 Scores on a Scale
Thermal Burns
Primary: Narcotic Consumption (Measured in mg/kg Narcotic Consumption) — 57.5; 67.75 mg/kg narcotic consumption
Metabolic Syndrome
Primary: Mean Low Density Lipoprotein Cholesterol in Blood — 70; 135 mg/dl
Myopia; Astigmatism
Primary: Proportion of Eyes With Monocular Visual Acuity Better Than 20/40 — 1.0 proportion of Subject Eyes
Nervous System Disorders
Primary: Assessment of the Long-term Safety of Dysport® Through the Collection of Treatment Emergent Adverse Events (TEAEs) — 102; 62; 47; 11 Participants
Gingival Recession · Tooth Abrasion
Primary: Percentage of Defect Coverage — 15; 14 Gingival recessions
Non-Hodgkin's Lymphoma
Primary: Progression-Free Survival in the Follicular Lymphoma Population, Investigator-Assessed — 24.0; 16.8 percentage of participants with event — p=0.0012
Gingival Recession
Primary: Percentage of Defect Coverage — 87.2; 77.4 percentage of root coverage
Atopic Dermatitis
Primary: Absolute Change From Baseline in Eczema Area and Severity Index (EASI) Total Score at Week 12 — -10.78; -13.67; -15.14; -15.72 units on a scale — p=0.143
Lymphoma
Primary: Progression-Free Survival (PFS) at 2 Years — 82; 81 percentage of participants
Smoking Cessation
Primary: 7-day Point Prevalence Abstinence From Cigarettes — 68; 56; 56 Participants — p=0.54
Hypotension · Pressure Ulcer
Primary: Accuracy as Indicated by Co-oximetry Measure of Arterial Oxygen Saturation — 43 Participants
Neuropathic Pain
Primary: Baseline Mean Pain Score — 6.41; 6.54 units on a scale
Herpes Zoster
Primary: Number of Subjects With Serious Adverse Events (SAEs) — 6; 2 Participants